Market Cap 5.06B
Revenue (ttm) 0.00
Net Income (ttm) -177.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 2.39
Volume 2,147,600
Avg Vol 1,541,074
Day's Range N/A - N/A
Shares Out 48.77M
Stochastic %K 63%
Beta 0.16
Analysts Strong Sell
Price Target $160.64

Company Profile

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 neg...

Industry: Biotechnology
Sector: Healthcare
Phone: (763) 392-0123
Address:
2800 Campus Drive, Suite 140, Minneapolis, United States
kellymone2
kellymone2 Jul. 15 at 6:47 AM
$CELC not at all. The approval targets PIK3CA wild-type disease, which represents roughly 60% of HR+/HER2− patients, while HR+/HER2− itself represents about 70% of all breast cancers. I would not call it dirty label
0 · Reply
mailman1961
mailman1961 Jul. 15 at 4:09 AM
$CELC didn't get chance to look but was there a dirty label. That AH price action is not what I epxected. I sold out back in the 90s but good luck top those who played thru.
0 · Reply
jb02345
jb02345 Jul. 15 at 3:07 AM
$CELC baker bros right again
0 · Reply
TheTarkioTrader
TheTarkioTrader Jul. 15 at 2:33 AM
$CELC So based on the filings I found, Baker Brothers had reported ownership of roughly 9.58 million CELC shares (beneficial ownership) in a prior Schedule 13D filing.  If the Form 144 represents a planned sale of about 3.1 million shares, then: 3.1 million ÷ 9.58 million ≈ 32% So they are looking to sell roughly one-third of their CELC position (not their entire stake). 
0 · Reply
TheTarkioTrader
TheTarkioTrader Jul. 15 at 2:24 AM
$CELC A Form 144 is not proof they already sold. It is a notice of intent to sell shares under Rule 144. The sale can happen after the filing, but it is not guaranteed. They may: • sell all of the shares, • sell only part of them, • delay the sale, • or not sell at all. For CELC, the market will likely focus on the size: • About 3.1 million shares planned • Roughly $300+ million in value if sold around the filing price (depending on the actual share price) • Baker Brothers is a major biotech investor, so their moves get attention. Is it negative? Short term, it can be. A large holder potentially selling creates fear of extra supply, and traders may sell ahead of the possibility.
0 · Reply
TheTarkioTrader
TheTarkioTrader Jul. 15 at 2:19 AM
$CELC 667, L.P. (connected to Baker Brothers) filed a Form 144, which is a notice that they plan to sell restricted/affiliate shares under SEC Rule 144.  • They are looking to sell 261,368 shares, worth about $26.8 million at the price used in the filing.  • Another Baker Brothers fund is filing separately to sell 2,838,632 shares, bringing the total planned sale to about 3.1 million shares. 
0 · Reply
Florestan
Florestan Jul. 15 at 2:04 AM
$CELC fully expected to see the approval. Where do I think this thing ends by EOY with commercialization + eventual approval of the MT label? Probably 180.
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jul. 15 at 12:39 AM
$CELC is now the latest addition to our list of 23 commercial-stage oncology focused bios with market caps north of $450MM. Congratulations to CELC No one asked but attached is a comparison of CELC's valuation as a multiple of 5 year (FY28 - 32) & 8-year (FY28 - 35) analyst consensus revenue estimates to 4 very recent peer M&A oncology & non-oncology transactions (all nearing commercial-stage like CELC yesterday). The comp is not perfect but does provide a barometer of CELC potential if analyst estimates are credible & if Gedatolisib is worth peer M&A multiples should CELC exit. This is not investment advice. We're merely sharing 1 analysis of many needed to assess potential. We will update CELC's multiples to its peer oncology focused bios shortly. $CRNX $XBI $IBB $APGE
0 · Reply
HboFam
HboFam Jul. 15 at 12:36 AM
$CELC PDUFA Dates are often sell the news events the Real value catalysts are Phase 3 Readouts, like the one coming at $SLS Should see a trading halt and a 5x to 15x gap up on the news
2 · Reply
TheTarkioTrader
TheTarkioTrader Jul. 15 at 12:31 AM
$CELC come on buddy the analyst had that approval priced and I’d love to think not but they did. It’s all good.
0 · Reply
Latest News on CELC
Celcuity Transcript: FDA announcement

Jul 14, 2026, 5:30 PM EDT - 11 hours ago

Celcuity Transcript: FDA announcement


Celcuity Press release: FDA announcement

Jul 14, 2026, 5:30 PM EDT - 11 hours ago

Celcuity Press release: FDA announcement


Celcuity Slides: FDA announcement

Jul 14, 2026, 5:30 PM EDT - 11 hours ago

Celcuity Slides: FDA announcement


Celcuity announces FDA approval of Revtorpyk

2026-07-14T20:55:11.000Z - 11 hours ago

Celcuity announces FDA approval of Revtorpyk


Celcuity Slides: Corporate presentation

Jul 14, 2026, 4:00 PM EDT - 12 hours ago

Celcuity Slides: Corporate presentation


US FDA approves Celcuity's breast cancer drug

Jul 14, 2026, 3:29 PM EDT - 13 hours ago

US FDA approves Celcuity's breast cancer drug


Celcuity Slides: FY 2026

Jun 10, 2026, 8:00 AM EDT - 4 weeks ago

Celcuity Slides: FY 2026


Celcuity prices $500M convertible senior note offering

2026-06-04T11:42:59.000Z - 5 weeks ago

Celcuity prices $500M convertible senior note offering


Celcuity falls -23.5%

2026-06-02T16:20:25.000Z - 6 weeks ago

Celcuity falls -23.5%


Celcuity falls -22.2%

2026-06-02T16:08:41.000Z - 6 weeks ago

Celcuity falls -22.2%


Celcuity Transcript: Study result

Jun 2, 2026, 8:00 AM EDT - 6 weeks ago

Celcuity Transcript: Study result


Celcuity Press release: Study result

Jun 2, 2026, 8:00 AM EDT - 6 weeks ago

Celcuity Press release: Study result


Celcuity Slides: Study result

Jun 2, 2026, 8:00 AM EDT - 6 weeks ago

Celcuity Slides: Study result


Celcuity To Participate in Upcoming Investor Conferences

May 28, 2026, 8:30 AM EDT - 6 weeks ago

Celcuity To Participate in Upcoming Investor Conferences


Celcuity price target raised to $175 from $150 at Stifel

2026-05-15T13:21:29.000Z - 2 months ago

Celcuity price target raised to $175 from $150 at Stifel


Celcuity price target raised to $183 from $150 at Wells Fargo

2026-05-15T11:00:19.000Z - 2 months ago

Celcuity price target raised to $183 from $150 at Wells Fargo


Celcuity reports Q1 adjusted EPS (86c) vs. (81c) last year

2026-05-14T21:44:38.000Z - 2 months ago

Celcuity reports Q1 adjusted EPS (86c) vs. (81c) last year


Celcuity Earnings Call Transcript: Q1 2026

May 14, 2026, 4:30 PM EDT - 2 months ago

Celcuity Earnings Call Transcript: Q1 2026


Celcuity Earnings release: Q1 2026

May 14, 2026, 4:30 PM EDT - 2 months ago

Celcuity Earnings release: Q1 2026


Celcuity Quarterly report: Q1 2026

May 14, 2026, 4:30 PM EDT - 2 months ago

Celcuity Quarterly report: Q1 2026


Notable companies reporting after market close

2026-05-14T20:12:10.000Z - 2 months ago

Notable companies reporting after market close

AMAT BOOT FIG


Celcuity rises 18.4%

2026-05-04T16:06:29.000Z - 2 months ago

Celcuity rises 18.4%


Celcuity rises 17.1%

2026-05-04T14:25:21.000Z - 2 months ago

Celcuity rises 17.1%


Celcuity Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 3 months ago

Celcuity Proxy statement: Proxy filing


Celcuity Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 3 months ago

Celcuity Proxy statement: Proxy filing


Celcuity Earnings Call Transcript: Q4 2025

Mar 25, 2026, 4:30 PM EDT - 3 months ago

Celcuity Earnings Call Transcript: Q4 2025


Celcuity Annual report: Q4 2025

Mar 25, 2026, 4:30 PM EDT - 3 months ago

Celcuity Annual report: Q4 2025


Celcuity Earnings release: Q4 2025

Mar 25, 2026, 4:30 PM EDT - 3 months ago

Celcuity Earnings release: Q4 2025


Celcuity Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 2:20 PM EDT - 4 months ago

Celcuity Transcript: Leerink Global Healthcare Conference 2026


Celcuity Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 10:30 AM EST - 4 months ago

Celcuity Transcript: TD Cowen 46th Annual Health Care Conference


Celcuity Appoints Charles Romp to its Board of Directors

Feb 12, 2026, 4:05 PM EST - 5 months ago

Celcuity Appoints Charles Romp to its Board of Directors


Celcuity Earnings Call Transcript: Q3 2025

Nov 12, 2025, 4:30 PM EST - 8 months ago

Celcuity Earnings Call Transcript: Q3 2025


Celcuity Quarterly report: Q3 2025

Nov 12, 2025, 4:30 PM EST - 8 months ago

Celcuity Quarterly report: Q3 2025


Celcuity Earnings release: Q3 2025

Nov 12, 2025, 4:30 PM EST - 8 months ago

Celcuity Earnings release: Q3 2025


Celcuity Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 10:00 AM EST - 8 months ago

Celcuity Transcript: Stifel 2025 Healthcare Conference


Celcuity Transcript: Study Result

Oct 20, 2025, 8:00 AM EDT - 9 months ago

Celcuity Transcript: Study Result


Celcuity Press release: Study Result

Oct 20, 2025, 8:00 AM EDT - 9 months ago

Celcuity Press release: Study Result


Celcuity Slides: Study Result

Oct 20, 2025, 8:00 AM EDT - 9 months ago

Celcuity Slides: Study Result


Celcuity Slides: Corporate Presentation

Oct 16, 2025, 7:00 AM EDT - 9 months ago

Celcuity Slides: Corporate Presentation


Celcuity Earnings Call Transcript: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 11 months ago

Celcuity Earnings Call Transcript: Q2 2025


Celcuity Earnings release: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 11 months ago

Celcuity Earnings release: Q2 2025


Celcuity Quarterly report: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 11 months ago

Celcuity Quarterly report: Q2 2025


Celcuity: What's Happening With CELC Stock?

Jul 29, 2025, 6:40 AM EDT - 1 year ago

Celcuity: What's Happening With CELC Stock?


Celcuity Transcript: Status Update

Jul 28, 2025, 8:00 AM EDT - 1 year ago

Celcuity Transcript: Status Update


Celcuity Slides: Status Update

Jul 28, 2025, 8:00 AM EDT - 1 year ago

Celcuity Slides: Status Update


Celcuity Slides: Corporate Presentation

Jun 30, 2025, 7:00 AM EDT - 1 year ago

Celcuity Slides: Corporate Presentation


Celcuity Earnings Call Transcript: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

Celcuity Earnings Call Transcript: Q1 2025


Celcuity Earnings release: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

Celcuity Earnings release: Q1 2025


Celcuity Quarterly report: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

Celcuity Quarterly report: Q1 2025


Celcuity Proxy statement: Proxy Filing

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Celcuity Proxy statement: Proxy Filing


Celcuity Proxy statement: Proxy Filing

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Celcuity Proxy statement: Proxy Filing


kellymone2
kellymone2 Jul. 15 at 6:47 AM
$CELC not at all. The approval targets PIK3CA wild-type disease, which represents roughly 60% of HR+/HER2− patients, while HR+/HER2− itself represents about 70% of all breast cancers. I would not call it dirty label
0 · Reply
mailman1961
mailman1961 Jul. 15 at 4:09 AM
$CELC didn't get chance to look but was there a dirty label. That AH price action is not what I epxected. I sold out back in the 90s but good luck top those who played thru.
0 · Reply
jb02345
jb02345 Jul. 15 at 3:07 AM
$CELC baker bros right again
0 · Reply
TheTarkioTrader
TheTarkioTrader Jul. 15 at 2:33 AM
$CELC So based on the filings I found, Baker Brothers had reported ownership of roughly 9.58 million CELC shares (beneficial ownership) in a prior Schedule 13D filing.  If the Form 144 represents a planned sale of about 3.1 million shares, then: 3.1 million ÷ 9.58 million ≈ 32% So they are looking to sell roughly one-third of their CELC position (not their entire stake). 
0 · Reply
TheTarkioTrader
TheTarkioTrader Jul. 15 at 2:24 AM
$CELC A Form 144 is not proof they already sold. It is a notice of intent to sell shares under Rule 144. The sale can happen after the filing, but it is not guaranteed. They may: • sell all of the shares, • sell only part of them, • delay the sale, • or not sell at all. For CELC, the market will likely focus on the size: • About 3.1 million shares planned • Roughly $300+ million in value if sold around the filing price (depending on the actual share price) • Baker Brothers is a major biotech investor, so their moves get attention. Is it negative? Short term, it can be. A large holder potentially selling creates fear of extra supply, and traders may sell ahead of the possibility.
0 · Reply
TheTarkioTrader
TheTarkioTrader Jul. 15 at 2:19 AM
$CELC 667, L.P. (connected to Baker Brothers) filed a Form 144, which is a notice that they plan to sell restricted/affiliate shares under SEC Rule 144.  • They are looking to sell 261,368 shares, worth about $26.8 million at the price used in the filing.  • Another Baker Brothers fund is filing separately to sell 2,838,632 shares, bringing the total planned sale to about 3.1 million shares. 
0 · Reply
Florestan
Florestan Jul. 15 at 2:04 AM
$CELC fully expected to see the approval. Where do I think this thing ends by EOY with commercialization + eventual approval of the MT label? Probably 180.
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jul. 15 at 12:39 AM
$CELC is now the latest addition to our list of 23 commercial-stage oncology focused bios with market caps north of $450MM. Congratulations to CELC No one asked but attached is a comparison of CELC's valuation as a multiple of 5 year (FY28 - 32) & 8-year (FY28 - 35) analyst consensus revenue estimates to 4 very recent peer M&A oncology & non-oncology transactions (all nearing commercial-stage like CELC yesterday). The comp is not perfect but does provide a barometer of CELC potential if analyst estimates are credible & if Gedatolisib is worth peer M&A multiples should CELC exit. This is not investment advice. We're merely sharing 1 analysis of many needed to assess potential. We will update CELC's multiples to its peer oncology focused bios shortly. $CRNX $XBI $IBB $APGE
0 · Reply
HboFam
HboFam Jul. 15 at 12:36 AM
$CELC PDUFA Dates are often sell the news events the Real value catalysts are Phase 3 Readouts, like the one coming at $SLS Should see a trading halt and a 5x to 15x gap up on the news
2 · Reply
TheTarkioTrader
TheTarkioTrader Jul. 15 at 12:31 AM
$CELC come on buddy the analyst had that approval priced and I’d love to think not but they did. It’s all good.
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Jul. 15 at 12:17 AM
$CELC THIS:::: Almost two years of cash at hand.
1 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Jul. 15 at 12:07 AM
$CELC Depending on the data provider: * 12 analysts: Strong Buy consensus * Average price target: ~$160.64 * Range: $145–175 One important caveat These targets were mostly issued before the FDA approval (many on June 2–3, 2026), when approval was expected but not guaranteed. Now that the approval risk has been removed, analysts typically update their models over the following days or weeks to reflect: * launch assumptions, * reimbursement expectations, * revenue forecasts, * peak sales estimates, * and valuation. That means it’s entirely possible we’ll see higher price targets if analysts become more optimistic about commercialization—or lower ones if they think the current share price already reflects much of the opportunity. Given the significance of the approval, I’d expect a fresh round of research notes and potentially revised targets over the next week or two as firms incorporate the regulatory outcome into their models.
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Jul. 15 at 12:02 AM
$CELC FDA APPROVED BABY * Drug: Gedatolisib * Disease: HR-positive, HER2-negative advanced breast cancer * Patient population: One of the largest breast cancer subtypes, accounting for roughly 70% of breast cancers. * Treatment setting: Patients whose disease has progressed after prior endocrine therapy. This is a large commercial market, with tens of thousands of eligible patients annually in the U.S. and many more worldwide.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 14 at 10:53 PM
$CELC @cubie totally Agree $SLS is about to 10x ...
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 14 at 10:52 PM
$CELC @cubie are you ready.
0 · Reply
Olivia_Strickland
Olivia_Strickland Jul. 14 at 10:47 PM
$CELC after-hours, down 6.36% since today's close.
0 · Reply
West_Bale
West_Bale Jul. 14 at 10:47 PM
$CELC The drug should work spectacularly in the first line setting. But it will take a long time to read out considering mPFS above 40 months. Much better than the high 20 months in the current standard of care.
0 · Reply
GhostTrading99
GhostTrading99 Jul. 14 at 10:43 PM
$CELC ignore after hour. This will be green in the morning . Shorts covering after hours by brining the price down
1 · Reply
HappyStockholder
HappyStockholder Jul. 14 at 10:34 PM
$CELC For a comparison to consider, MDGL was trading around $245 when its PDUFA was approved in March 2024. It proceeded to drop slightly, and then rise when the product was launched. Today it closed at $536.86. All time high was $615.
0 · Reply
West_Bale
West_Bale Jul. 14 at 10:31 PM
$CELC Another derisking event. All eyes on the P2 CRPC results at year end. Betting on positive results based on the proven mechanism of action on breast cancers.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 14 at 10:23 PM
$SLS $CELC Not Complicated. Its why SLS’ share price, market value, funds Invested, cash are all Up 10x + since the IDMC Unblinded actual MOS and IR data from the Phase 3 Interim Analysis.
2 · Reply
earsopenmouthclosed
earsopenmouthclosed Jul. 14 at 10:19 PM
$CELC I thought this was $CELH whaddsfuck man
0 · Reply